Overall, our results indicate that VEGF-B has therapeutic potential, as the cardiac hypertrophy induced by VEGF-B does not progress into pathological cardiac remodeling or heart failure even in aged rats, and the VEGF-B induced hypertrophic and metabolic changes are beneficial in myocardial ischemia. Here, VEGFB is linked to heart failure.